4 results about "Coagulation Factor IX" patented technology

The present invention relates to bispecific antibodies capable of binding to coagulation Factor IX (FIX) and / or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and / or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A with or without inhibitors.

The application belongs to the technical field of biological medicine, and particularly relates to a kit for coagulation factor IX detection and a preparation method thereof. The kit for coagulation factor IX detection comprises monoclonal antibody RFactor IX-1 coupled receptor microspheres, biotin-labeled monoclonal antibody RFactor IX-2, streptavidin-coupled donor microspheres, a standard, a standard buffer, and a 96-well white detection plate. The coagulation factor IX detection kit provided by the application has the advantages of simple operation, high precision, strong specificity, good stability and the like, can meet the needs of clinical efficient, accurate and stable detection of coagulation factor IX, and has a good clinical application prospect.

This invention relates to a gene encoding coagulation factor IX. F9 This study investigates animal models of nonsense mutations, methods for screening hemophilia drugs using these models, and the application of the screened stRNAs in the preparation of hemophilia drugs. Based on an analysis of the probability of nonsense mutations in coagulation factor IX in hemophilia patients, the study verifies that stRNAs can read the coagulation factor IX encoding gene. F9 The function and efficiency of the premature termination codon (PTC) were investigated. Seven Arg-stRNAs were designed to target the coagulation factor IX R75* mutation, and readthrough efficiency was tested at the cellular level. A mouse model of the coagulation factor IX R75* mutation was constructed, and Arg-stRNA was delivered via AAV, restoring the expression of endogenous coagulation factor IX and reducing clotting time, demonstrating the effectiveness of stRNA in treating hemophilia B.

An objective of the present disclosure is to provide effective pharmaceutical compositions and dosage regimens for preventing and / or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors found that categorized flat dosing (CFD) of emicizumab can provide therapeutic effects and safety that are comparable with those of per-kg dosing (PKD), as well as more simplified, less wasteful regimens and enables administration with injectable device such as an autoinjector or syringe.